In a significant development, Johnson & Johnson has announced its decision to pay approximately £5.5 billion to resolve a multitude of lawsuits claiming that its talc-based products, including baby powder, have been linked to ovarian cancer. This agreement, which encompasses around 76,000 claims, has the potential to bring closure to a protracted legal battle that has spanned over a decade.
The Scope of the Settlement
The settlement aims to cover nearly all remaining talc-related claims against Johnson & Johnson, including those consolidated in federal court in New Jersey and various state cases. This landmark resolution arises after the company had previously settled most allegations related to its talc products containing asbestos, which were implicated in cases of mesothelioma.
Plaintiffs’ law firms have welcomed the agreement as a beneficial resolution following years of litigation. However, for the settlement to be finalised, it must receive acceptance from 95% of the ovarian cancer claimants involved in state or federal court proceedings.
Legal Context and Company Stance
Erik Haas, Johnson & Johnson’s vice-president of litigation, described the claims as “meritless” but expressed the company’s willingness to settle in order to achieve closure. “While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” he stated.
The settlement is structured to allocate specific values to qualifying ovarian cancer claims, but it does not impose a cap on the total amount Johnson & Johnson might pay. Legal representatives involved in the negotiations, such as Chris Seeger, who represents approximately 2,500 clients, indicated that the total payout could exceed £5.5 billion, potentially reaching £6 billion or more depending on claimant participation.
Recent Legal Developments
This settlement comes on the heels of several victories for Johnson & Johnson in court, which included successful challenges against plaintiffs’ lawyers and doubts cast by a federal judge over the ability of individual plaintiffs to establish a direct causal link between talc and ovarian cancer.
Despite these legal victories, Johnson & Johnson has historically denied any allegations linking its talc products to cancer, asserting that they are safe and free of asbestos. In 2020, the company ceased the sale of talc-based baby powder in the United States, opting instead for a cornstarch-based alternative. However, litigation resumed in March 2025 after an unsuccessful strategy involving multiple bankruptcies through a subsidiary, which aimed to manage and settle the ongoing cases.
Implications for Future Claims
It is essential to note that this settlement specifically addresses existing claims and does not provide a framework for future lawsuits. This distinction has allowed for a more immediate financial relief for current plaintiffs compared to the proposed bankruptcy settlements, which would have extended payouts over a more protracted timeline. According to Seeger, the agreement stipulates that all claims will be settled within 18 months, a significant acceleration compared to the previous decade-long wait.
Why it Matters
This settlement represents a pivotal moment not only for the claimants seeking justice but also for the broader public health discourse surrounding the safety of consumer products. The outcome of this case may influence future litigation in the pharmaceutical and consumer goods sectors, particularly as companies face increasing scrutiny over product safety and transparency. As such, the resolution of this long-standing legal battle could set important precedents for how similar cases are managed and the responsibilities corporations bear in ensuring the safety of their products.